Selective serotonin reuptake inhibitor

Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA on TNX-601 CR for the Treatment of Major Depressive Disorder

Retrieved on:

Monday, March 22, 2021

Tonix Pharmaceuticals, Psychoactive drugs, Chemical compounds, Seth Lederman, Chloroarenes, Organic compounds, Tianeptine, Selective serotonin reuptake inhibitor, Bioequivalence

Tonixs TNX-601 CR is a novel oral formulation which is being developed as a potential treatment for MDD, posttraumatic stress disorder, and neurocognitive dysfunction associated with corticosteroid use.

Key Points:

Tonixs TNX-601 CR is a novel oral formulation which is being developed as a potential treatment for MDD, posttraumatic stress disorder, and neurocognitive dysfunction associated with corticosteroid use.
We are pleased with the results of the FDA meeting on developing TNX-601 CR for the treatment of MDD and we look forward to advancing its clinical development, said Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals.
We believe that with respect to tianeptine, TNX-601 CR would meet the bioequivalence standard for daily dosing of these immediate release (IR) products.
Given tianetptines unique metabolic pathway, we believe that TNX-601 CR has a reduced risk of drug-drug interactions compared to SSRIs5.

Dr. Ashraf Hanna's Innovative Ketamine Protocol Delivers a Complete Sustained Remission in a Patient with Depression and Suicidal Ideation

Retrieved on:

Tuesday, October 6, 2020

Drugs, Psychoactive drugs, RTT, Branches of biology, Psychiatric diagnosis, Antidepressants, Amines, Ketamine, Treatment-resistant depression, Post-traumatic stress disorder, Selective serotonin reuptake inhibitor, Obsessive–compulsive disorder

Many prominent psychiatrists describe Ketamine as fast and effective with results in a matter of days or hours which is a huge advantage over traditional SSRIs.

Key Points:

Many prominent psychiatrists describe Ketamine as fast and effective with results in a matter of days or hours which is a huge advantage over traditional SSRIs.
IV Ketamine therapy is only reserved for those patients that have treatment-resistant depression and have failed conventional therapy.
I then wanted to expand the treatment for PTSD, depression, bipolar depression and obsessive compulsive disorders.
For more information regarding IV Ketamine Infusion therapy for Depression and PTSD , please visit: https://www.ivketamine.com orcall 727-538-2646

Are some antidepressants less risky for pregnant women?

Retrieved on:

Wednesday, January 8, 2020

Branches of biology, Depression, Neuroscience, Proteins, Antidepressant, RTT, Serotonin transporter, Serotonin, Aromatase, Management of depression, Selective serotonin reuptake inhibitor

Prescribing antidepressants for pregnant women is controversial.

Key Points:

Prescribing antidepressants for pregnant women is controversial.
The harmful effects of antidepressants are thought to be due to their interaction with certain key hormones.
Most antidepressants prescribed to pregnant women target serotonin, a hormone produced both in the brain and, as shown by Professor Vaillancourt's team in 2017, in the placenta.
"We wanted to see how the antidepressants that have been developed to block the serotonin transporter also affect aromatase.

SPRAVATO®▼ (Esketamine) Nasal Spray Approved in Europe for Adults with Treatment-Resistant Major Depressive Disorder

Retrieved on:

Thursday, December 19, 2019

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has approved SPRAVATO (esketamine) nasal spray, in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI), for adults living with treatment-resistant major depressive disorder (TRD).

Key Points:

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has approved SPRAVATO (esketamine) nasal spray, in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI), for adults living with treatment-resistant major depressive disorder (TRD).
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development of SPRAVATO.
FDA advisory committee recommends approval of SPRAVATOTM (esketamine) nasal spray CIII for adults with treatment-resistant depression.
Janssen Announces US FDA approval of SPRAVATOTM (esketamine) CIII nasal spray for adults with Treatment-Resistant Depression (TRD) who have cycled through multiple treatments without relief.

Researchers Find Antidepressants Significantly Increase Risk of Gastrointestinal, Intracranial Bleeding

Retrieved on:

Wednesday, January 30, 2019

Medical specialties, Medicine, Branches of biology, Gastrointestinal tract disorders, Bleeding, Transfusion medicine, Selective serotonin reuptake inhibitor, Intracranial hemorrhage, Stress ulcer, Drotrecogin alfa

However, they also carry risks for gastrointestinal and intracranial bleeding that compound when taken with other medications.

Key Points:

However, they also carry risks for gastrointestinal and intracranial bleeding that compound when taken with other medications.
While gastrointestinal bleeding is most common, in rare instances patients can develop intracranial bleeding, which is a life-threatening event.
Yuet says that the risk for bleeding is well established but not well known among patients.
She also recommends physicians monitor their patients closely for symptoms of gastrointestinal bleeding during the first 30 days of SSRI therapy, especially if patients are taking concurrent medications that may increase bleeding risk.